PFIZER INC. (PFE)
Market CLOSE
SOURCE; NYSE
As of May 16, 2012 4:00 pm. Quotes are delayed by at least 15 minutes
|
$22.64 Last Trade |
+0.34 Change |
39,465,824 Volume |
$22.30 Prev. Close |
|
+1.52% Change (%) |
zack's rank
market grader
- No Market Grader available for this symbol.
FOX BUSINESS NEWS ON PFE
- FDA Panel Recommends Approval Of Pfizer's Tofacitinib - May 09, 2012
- Abbott To Pay $1.6 Billion To Settle Depakote Marketing Probes - May 07, 2012
- Pfizer Axes Late-Stage Lyrica Study - May 04, 2012
- FDA Approves Protalix, Pfizer Drug To Treat Gaucher Disease - May 01, 2012
- US Stocks Rally After Factory Data; DJIA Hits Multiyear High - May 01, 2012
- Wall Street Kicks Off May in Rally Mode - May 01, 2012
- Dow Notches Four-Year Closing High - May 01, 2012
- Pfizer Profit Falls 19% As Generics Hurt Lipitor Sales - May 01, 2012
- UPDATE: Pfizer Profit Falls 19% As Generics Hurt Lipitor Sales - May 01, 2012
partner headlines ON PFE
- Pfizer in Transition - The Motley Fool
- Your Warning Label Is My Sales Brochure - The Motley Fool
- Manufacturing Facility Cleared at BMY - Analyst Blog - Zacks
- Manufacturing Facility Cleared at BMY - Analyst Blog - Nasdaq
- Panel Votes in Favor of Pfizer Drug - Analyst Blog - Zacks
- Panel Votes in Favor of Pfizer Drug - Analyst Blog - Nasdaq
- UPDATE: Pfizer Says Didn't Meet Primary Endpoint - Benzinga
- This Biotech's for Sale! Reportedly. - The Motley Fool
- S&P Bullish On Biotech ETFs (FBT, IBB, XBI) - Benzinga
- VIVUS Is A Viable Long Term Investment - The Motley Fool
- Why Greece Is Dragging Down the Dow - The Motley Fool
- A Different Idea for Investing in Health Care - The Motley Fool
- Is This Biotech Upgrade Deserved? - The Motley Fool
- Investors Seeking Defensive Stocks Where 3% to Over 5% Dividends Rule! - 24/7 Wall St.
- Generics Drive Dr. Reddy's - Analyst Blog - Zacks
- Generics Drive Dr. Reddy's - Analyst Blog - Nasdaq
- Stocks Fall More Than 1% as Bank News Stings - Barron's
- This Just In: Upgrades and Downgrades - The Motley Fool
- The 10 Most Fascinating Things I Read This Week - The Motley Fool
- MDVN Misses; Focus on Enzalutamide - Analyst Blog - Zacks
